Antisense oligonucleotides (ASOs) hold promise for gene-specific knockdown in diseases that involve RNA or protein gain-offunction effects. In the hereditary degenerative disease myotonic dystrophy type 1 (DM1), transcripts from the mutant allele contain an expanded CUG repeat 1-3 and are retained in the nucleus 4,5 . The mutant RNA exerts a toxic gain-of-function effect 6 , making it an appropriate target for therapeutic ASOs. However, despite improvements in ASO chemistry and design, systemic use of ASOs is limited because uptake in many tissues, including skeletal and cardiac muscle, is not sufficient to silence target messenger RNAs 7,8 . Here we show that nuclear-retained transcripts containing expanded CUG (CUG exp ) repeats are unusually sensitive to antisense silencing. In a transgenic mouse model of DM1, systemic administration of ASOs caused a rapid knockdown of CUG exp RNA in skeletal muscle, correcting the physiological, histopathologic and transcriptomic features of the disease. The effect was sustained for up to 1 year after treatment was discontinued. Systemically administered ASOs were also effective for muscle knockdown of Malat1, a long non-coding RNA (lncRNA) that is retained in the nucleus 9 . These results provide a general strategy to correct RNA gain-of-function effects and to modulate the expression of expanded repeats, lncRNAs and other transcripts with prolonged nuclear residence.
Antisense oligonucleotides (ASOs) hold promise for gene-specific knockdown in diseases that involve RNA or protein gain-offunction effects. In the hereditary degenerative disease myotonic dystrophy type 1 (DM1), transcripts from the mutant allele contain an expanded CUG repeat [1] [2] [3] and are retained in the nucleus 4, 5 . The mutant RNA exerts a toxic gain-of-function effect 6 , making it an appropriate target for therapeutic ASOs. However, despite improvements in ASO chemistry and design, systemic use of ASOs is limited because uptake in many tissues, including skeletal and cardiac muscle, is not sufficient to silence target messenger RNAs 7, 8 . Here we show that nuclear-retained transcripts containing expanded CUG (CUG exp ) repeats are unusually sensitive to antisense silencing. In a transgenic mouse model of DM1, systemic administration of ASOs caused a rapid knockdown of CUG exp RNA in skeletal muscle, correcting the physiological, histopathologic and transcriptomic features of the disease. The effect was sustained for up to 1 year after treatment was discontinued. Systemically administered ASOs were also effective for muscle knockdown of Malat1, a long non-coding RNA (lncRNA) that is retained in the nucleus 9 . These results provide a general strategy to correct RNA gain-of-function effects and to modulate the expression of expanded repeats, lncRNAs and other transcripts with prolonged nuclear residence.
Antisense silencing by the RNase H-dependent mechanism entails a three-step process of oligonucleotide hybridization to its cognate RNA, cleavage of the target by RNase H1 and exonuclease degradation of the cleavage fragments. The relative efficiency of this mechanism in the nucleus and cytoplasm is uncertain. Observations that ASOs shuttle from cytoplasm to nucleus 10 and that targeting intronic sequences 11 or nuclear RNA 12 can silence gene expression indicate that antisense is active in the nucleus. However, activity in the cytoplasm is less clear. Although RNase H1 is not restricted to the nucleus 13 , recent studies indicate that the non-nuclear fraction is confined to mitochondria 14 . This suggests that ASONRNase H cleavage is mainly a nuclear process, whose potency could be maximized by targeting transcripts with long nuclear residence.
To test this idea, we used a transgenic mouse model of DM1. HSA LR transgenic mice express CUG exp RNA at high levels in skeletal muscle. Human DM1 is caused by an expanded CTG repeat in the 39 untranslated region (UTR) of dystrophia myotonica-protein kinase (DMPK) 3 , whereas in HSA LR mice the expanded repeat is in the 39 UTR of a human skeletal actin (hACTA1) transgene 6 . In both conditions the CUG exp transcripts are retained in nuclear foci, along with splicing factors in the muscleblind-like (MBNL) protein family. Muscleblind sequestration leads to misregulated alternative splicing and other changes of the muscle transcriptome [15] [16] [17] . The RNA toxicity was mitigated in mice by CAG-repeat morpholino oligomers that compete with MBNL proteins for CUG exp binding, without activating RNase H. However, this approach required direct injection into a single muscle, followed by in vivo electroporation, a method to load muscle fibres with oligomers 18 . As an alternative, RNase H-active ASOs could produce widespread correction, provided that uptake of circulating ASOs was sufficient to induce target cleavage.
We identified ASOs showing a strong knockdown of hACTA1 in tissue culture, good tolerability when systemically administered in wild-type mice, and activity against hACTA1-CUG exp transcripts in vivo when electroporated into muscle ( Supplementary Figs 1-3 ). The ASOs had 29-O-methoxyethyl (MOE) modifications at both ends to maximize biostability, and a central gap of 10 unmodified nucleotides to support RNase H activity (MOE gapmers; Supplementary Table 1 ). We tested three of the ASOs in HSA LR transgenic mice by subcutaneous injection of 25 mg kg 21 twice weekly ( Fig. 1a ). After 4 weeks of administration (8 injections), ASO 445236 reduced the level of CUG exp RNA in hindlimb muscles by more than 80% ( Fig. 1b ). Another ASO targeting the 39 UTR, downstream of the repeat tract, also showed strong CUG exp reduction, whereas an ASO targeting the 59 UTR, or three oligonucleotides against other targets, had no effect ( Fig. 1b, c) .
RNase H cleavage of mRNA is usually followed by rapid decay of cleavage fragments. However, stable cleavage fragments are observed occasionally 19 , and the CUG exp tract forms extensive hairpins 20 and ribonucleoprotein complexes 21 that could inhibit exonuclease activity. The failure of antisense targeting in the 59 UTR also raised the possibility that cleavage downstream of the repeat tract was required for efficient silencing. We therefore tested an additional ASO, 190401, targeting the hACTA1 coding region, and found that it also was highly effective ( Fig. 1d ). Furthermore, northern blot analysis using a CAGrepeat probe showed no evidence for a stable CUG exp cleavage fragment ( Fig. 1e ), and in situ hybridization showed reduction of nuclear CUG exp foci ( Supplementary Fig. 4 ). These results indicate that expanded CUG repeats are degraded after a cleavage event 59 or 39 of the repeat tract.
Reduction of CUG exp RNA would be expected to release sequestered MBNL1 protein and improve its splicing regulatory activity. Consistent with this prediction, alternative splicing of four MBNL1dependent exons, Serca1 (also known as Atp2a1) exon 22, titin (Ttn) exon 362, Zasp (also known as Ldb3) exon 11, and Clcn1 chloride ion channel exon 7a, was normalized ( Fig. 1f , g and Supplementary Figs 5 and 6) 15 . The Clcn1 splicing defect causes loss of channel function, repetitive action potentials and delayed muscle relaxation (myotonia) 22 , a cardinal feature of the disease. Blind analysis showed that myotonic discharges in hindlimb muscles were eliminated by the active ASOs ( Fig. 1h ), indicating rescue of Clcn1 function.
In addition to splicing defects, expression of CUG exp RNA or ablation of Mbnl1 causes extensive remodelling of the muscle transcriptome 16, 17, 23 . We used microarrays to examine transcriptomic effects of ASOs. Principle component analysis showed that gene expression in ASOtreated HSA LR mice was shifted towards wild-type mice, indicating an overall trend for transcriptome normalization ( Fig. 2a ). Among transcripts that were up-or downregulated in HSA LR muscle, more than 85% were normalized or partially corrected by ASOs, without evidence of off-target effects ( Fig. 2b , and Supplementary Fig. 7 and Supplementary Table 2 ). These results confirm that ASOs caused an overall improvement of the muscle transcriptome.
ASO effects were evident within 2 weeks ( Supplementary Fig. 8 ) and were dose-dependent. A threefold dose reduction (8.5 mg kg 21 biweekly for 4 weeks) caused partial myotonia and splicing correction, whereas a tenfold dose reduction (2.5 mg kg 21 ) caused partial myotonia correction in tibialis anterior but not in quadriceps ( Supplementary Fig. 9a -c), the latter muscle having higher basal levels of CUG exp expression 18 . Serum chemistries showed no evidence for renal or liver toxicity ( Supplementary Fig. 10 ).
A uniform finding in previous studies of MOE gapmer ASOs was that systemic administration failed to cause significant target reduction in muscle, despite efficient knockdown in liver (n 5 12 different mRNA targets; Supplementary Table 3 ), raising the possibility that muscle tissue in our model is unusually susceptible to antisense silencing. We examined the functional integrity of the muscle 
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membrane, a physiological barrier to ASO uptake 24 , and found that muscle penetration of the extracellular dye, Evans Blue, was similar in HSA LR and wild-type mice ( Supplementary Fig. 11a ). Direct analysis of muscle tissue indicated that ASO accumulation was no greater in HSA LR mice than in wild-type controls ( Supplementary Fig. 11b , c). Likewise, the mRNA level for RNase H1 was similar in HSA LR and wild-type muscle ( Supplementary Fig. 12 ). We tested ASOs targeting other muscle-expressed transcripts. ASOs for Pten phosphatase or Srb1 (also known as Scarb1) scavenger receptor showed efficient target knockdown in liver, but no appreciable knockdown in HSA LR or wildtype muscle (Fig. 3a ). Taken together with previous studies, our results indicate specific sensitivity of hACTA1-CUG exp transcripts rather than a general enhancement of ASO activity in HSA LR muscle. A notable metabolic feature of hACTA1-CUG exp and human DMPK-CUG exp mRNA is that processing and polyadenylation are normal but the transcripts are retained in the nucleus 5, 6 . Recent studies have shown that RNase H1, the enzyme responsible for antisense knockdown, is localized to the nucleus and mitochondria 14 , suggesting that antisense cleavage of nuclear-encoded RNA occurs before nuclear export, and raising the possibility that nuclear-retained transcripts may exhibit enhanced sensitivity. To determine whether other nuclear-retained transcripts show a similar effect we examined metastasis associated lung adenocarcinoma transcript 1 (Malat1), an endogenous nuclear lncRNA 9 . We identified MOE gapmer ASOs that produced strong Malat1 knockdown in cells, in an RNase H1-dependent manner ( Supplementary Fig. 13 ). In wild-type and HSA LR mice, subcutaneous administration of ASOs for 4 weeks caused a greater than 80% reduction in Malat1 in muscle (Fig. 3b, c) , supporting the idea that nuclear-retained transcripts have enhanced sensitivity.
To determine the duration of ASO action in muscle, we examined mice at 15 and 31 weeks after ASO was discontinued, and found that hACTA1-CUG exp knockdown and splicing correction remained strong (not shown). One year after ASO injection was discontinued, target reduction by ASO 190401 had waned, but remained approximately 50% or more for ASO 445236 (Fig. 4a ). Even at this late time point the appropriate cleavage products were detected by amplification of complementary DNA 59 ends (59 RACE), indicating persistent ASO-RNase H1 activity (Fig. 4b) . Consistent with the extent of target reduction, there was partial return of myotonia and splicing defects for 
LETTER RESEARCH
ASO 190401, whereas correction by ASO 445236 remained strong (Fig. 4c, d and Supplementary Fig. 14a-e ). Furthermore, the persistent knockdown of CUG exp RNA largely prevented the age-dependent myopathic changes in HSA LR muscle, as evidenced by reduced frequency of central nuclei (Fig. 4e ) and improved muscle-fibre diameter (mainly a prevention of fibre atrophy) ( Supplementary Fig. 15 ). These findings indicate that ASO activity against hACTA1-CUG exp in muscle is remarkably durable and that long-term reduction of the toxic RNA can protect against structural changes in muscle fibres. Notably, the duration of Malat1 knockdown in muscle was also prolonged (a greater than 50% reduction at 31 weeks after ASO discontinuation) and more persistent than in liver ( Supplementary Fig. 16 ).
Therapeutic application of this strategy to human DM1 will require transfer of the targeting sequence to hDMPK. We developed MOE gapmer ASOs that were active against hDMPK in cells. We examined in vivo activity after 4 weeks of twice weekly subcutaneous injection in transgenic mice that express hDMPK with 800 CUG repeats. The ASO produced significant knockdown of hDMPK-CUG exp transcripts in hindlimb muscle ( Fig. 4f and Supplementary Figs 17 and 18) , supporting the feasibility of silencing the pathogenic DMPK allele.
Despite physiological barriers to tissue uptake, our results indicate that systemic targeting of CUG exp RNA is feasible because small amounts of ASOs that enter muscle fibres can hybridize their target and productively engage RNase H1. Although the mechanisms for enhanced sensitivity of CUG exp RNA and Malat1 are not fully defined, our data suggest that residence time in the nucleus is an important determinant of transcript sensitivity. Features of the nuclear environment that may enhance antisense activity include nuclear localization of RNase H1 (ref. 14) and auxiliary proteins that promote oligonucleotide hybridization 25 , and-in the case of CUG exp transcripts-spatial concentration of targets in a small volume 4 . A similar approach may be effective for other genetic disorders that have nuclear accumulation of repeat expansion RNA 26, 27 . Previous studies have used CAG-repeat ASOs that bind CUG exp RNA without activating RNase H, in an effort to block the protein interactions or modify the metabolism of the toxic RNA 18, 28 . Although this approach was effective with local delivery, initial attempts at systemic delivery were less successful (T.M.W. and C.A.T., unpublished observations), which fits with the expectation that higher tissue concentrations of ASO are required to occupy CUG exp binding sites than to induce RNase H cleavage. Furthermore, the RNase H mechanism is attractive because it exploits the nuclear retention phenomenon to gain a therapeutic advantage, while posing less risk of off-target effects by avoiding a repetitive sequence. Recently, local delivery of RNase H-active CAG-repeat ASOs induced partial CUG exp knockdown, but was accompanied by muscle damage 29 , again suggesting that direct targeting of the repeat tract may have pitfalls. Our results also suggest that ASOs are useful for in vivo functional characterization and therapeutic modulation of lncRNAs, a large and recently recognized class of regulatory RNAs 30 .
METHODS SUMMARY
Experimental mice. All animal experiments were approved by the Institutional Animal Care and Use Committees at the University of Rochester, Genzyme Corporation and Isis Pharmaceuticals. Subcutaneous injection of ASOs. MOE gapmer ASOs were dissolved in saline and administered by subcutaneous injection in the interscapular region twice per week at the indicated doses. Quantitative real-time RT-PCR (polymerase chain reaction with reverse transcription) assay. Total RNA was purified from muscle using RNeasy Lipid Tissue Mini Kits (Qiagen). mRNA levels for ACTA1, Srb1, Pten, Malat1 and RNase H1 were determined on the Applied Biosystems 7500 System using 18S rRNA as normalization control. General transcription factor 2b (Gtf2b) and total RNA (Ribogreen assay) served as normalization controls for human DMPK and mouse Dmpk. Northern analysis. CUG exp sequences were detected using a 32 P end-labelled (CAG) 9 DNA oligonucleotide probe. Electromyography. Electromyography (EMG) was carried out blind under general anaesthesia, as described previously 18 .
RT-PCR analysis of alternative splicing. RT-PCR was carried out using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase (Invitrogen) and the same gene-specific primers for cDNA synthesis and PCR amplification. PCR products were separated on agarose gels, stained with SybrGreen I Nucleic Acid Gel Stain (Invitrogen) and scanned with a fluorimager. Transcriptome analysis. Quadriceps-muscle RNA from wild-type or HSA LR transgenic mice treated with vehicle (saline), ASO 445236 or ASO 190401 was processed to cRNA and hybridized on microbeads using MouseRef-8 v2.0 Expression BeadChip Kits (Illumina). Image data were quantified using BeadStudio software (Illumina). a-e, Two-month-old HSA LR mice received saline or ASO by subcutaneous injection of 25 mg kg 21 twice weekly for 4 weeks (n 5 5 for each ASO, n 5 6 for saline), with tissues isolated 1 year after the final dose. qRT-PCR analysis of HSA LR transgene mRNA (mean 6 s.d.) was normalized to the housekeeping gene Gtf2b mRNA (a). Results were similar when normalized to total RNA input. 59 RACE was carried out on muscle RNA obtained 1 week or 1 year after discontinuation of ASO 190401 or 445236 treatment (b). PCR products (59 RACE fragment) migrated at the expected position for ASONRNase H cleavage products, and were confirmed by DNA sequencing. Quantification of Serca1 splicing (c) and myotonia (d) showed a partial return of splicing defects and myotonia for ASO 190401 but not ASO 445236. Myotonia was graded blind by the examiner (d). After prolonged knockdown of toxic RNA, the number of internal nuclei per muscle fibre was determined by histologic analysis when mice were aged 14 months (e) (n 5 4 for ASO 445236; n 5 3 for saline; WT, untreated 3-month-old FVB/N wild-type control mice). f, DM328XL mice received subcutaneous injections of saline or ASO 445569 targeting the 39 UTR of hDMPK. The ASO dose was 50 or 75 mg kg 21 twice weekly for 4 weeks (n 5 5, low dose; n 5 4, high dose; n 5 2, saline). Tissues were isolated 2 days after the final dose. Dose-dependent reduction of hDMPK, normalized to housekeeping gene Gtf2b mRNA. Note that hDMPK mRNA was undetectable in wild-type mice. No RT, no reverse transcriptase. WT, untreated wild-type littermates of DM328XL transgenic mice (n 5 2). Error bars are mean 6 s.d. *P , 0.05, **P , 0.001, ***P , 0.0001 for ASO-treated versus saline-treated muscle (two-way ANOVA).
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METHODS
Antisense oligonucleotides. ASOs were synthesized at Isis Pharmaceuticals, as described previously 31 . All ASOs were MOE gapmer 20mers with phosphorothioate as the intersubunit linkage, 29-O-(2-methoxyethyl) (MOE) modifications of 5 nucleotides at the 59 and 39 end, and a central gap of 10 deoxynucleotides. The sequence of each ASO is listed in Supplementary Table 1 . CAG25 and GAC25 morpholinos 18 were purchased (Gene Tools). Identification of active ASOs. The criteria for identifying active hACTA1targeting ASOs were as follows: first, selection of targeting sequences that were not conserved in mice, to avoid knockdown of endogenous skeletal actin; second, .50% hACTA1 knockdown when electroporated in HepG2 cells ( Supplementary  Fig. 1) ; and third, absence of hepatotoxic or immunostimulatory effects in wildtype mice, when 50 mg kg 21 was injected subcutaneously twice weekly for 4 weeks ( Supplementary Fig. 2a-c) . Out of 11 candidate ASOs examined, 5 satisfied these criteria. For the ASO with the highest activity in HepG2 cells, we also verified activity against hACTA1-CUG exp transcripts in vivo, by direct injection and electroporation of tibialis anterior muscle in HSA LR mice ( Supplementary Fig. 3 ). Four of the five ASOs were subsequently used for subcutaneous administration in HSA LR mice. ASOs targeting Malat1 were identified by demonstration of .50% target knockdown when electroporated in mouse hepatocellular SV40 large T-antigen carcinoma (MHT) cells, and absence of hepatotoxic or immunostimulatory effects in wild-type mice (dosing as above). Cell transfection and gene analysis. HepG2 cells were electroporated in a 96-well plate format at 165V with ASOs in complete media containing MEM, nonessential amino acid (NEAA), sodium pyruvate and 10% FBS at room temperature. Cells were incubated overnight and lysed in RLT buffer (Qiagen). Total RNA was prepared using Qiagen RNeasy kit. Quantitative real time RT-PCR (qRT-PCR) was performed using the Qiagen QuantiTect Probe RT-PCR kit. Twenty-microlitre qRT-PCR reactions were run in duplicate and normalized against total RNA, calculated using the Ribogreen assay (Invitrogen). Experimental mice. Institutional Animal Care and Use Committees at the University of Rochester, Genzyme Corporation and Isis Pharmaceuticals approved all animal experiments. HSA LR mice in the line 20b were derived and maintained on the FVB/N background strain 6 . The (CTG) 250 tract in this line is unstable, and has shortened to (CTG) 220 . DM328XL mice carry a 45-kb human genomic fragment that includes the mutant DMPK gene with 800 CTG repeats 32, 33 . The DM328XL mice were hemizygous and display no histologic changes, myotonia or splicing defects in skeletal muscle 34, 35 . FVB/N, BALB/c, C57Bl/10 and Mdx mice were from Jackson Laboratories. Muscle injection of ASOs. The tibialis anterior muscle was injected with 0.2, 0.4 or 0.8 nmol ASO in 20 ml saline, and the contralateral tibialis anterior with 20 ml saline alone, they were then electroporated, as described previously 36 . Treatment assignments were randomized and injections were carried out blind. Subcutaneous injection of ASOs. All ASOs were dissolved in phosphate buffered saline (PBS). Doses of 2.5, 8.5, 12.5, 25 or 50 mg kg 21 were injected subcutaneously, twice per week in the interscapular region for 3.5 to 4 weeks (7 or 8 doses in total). Injection volumes ranged from 140 to 200 ml. Real-time PCR Assay. Total RNA was purified from tibialis anterior, gastrocnemius or quadriceps muscle using the RNeasy Lipid Tissue Mini Kit (Qiagen) according to the manufacturer's instructions. qRT-PCR was used to determine mRNA levels for ACTA1, Srb1, Pten, Malat1 and RNase H1, with 18S rRNA as normalization control, on an Applied Biosystems 7500 Real-Time PCR System. Gtf2b and total RNA (Ribogreen assay) served as normalization controls for human DMPK and mouse Dmpk.
